Morphine Injection Recalled for Lack of Sterility Assurance
Central Admixture Pharmacy Services Inc. is recalling morphine injections nationwide due to inadequate validation of sterilization procedures, which poses a potential sterility risk.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with lack of sterility assurance in an injectable drug product. No illnesses or injuries reported, but this is a risk-of-harm product where sterility failures in injectables could cause serious infection.
Plain-English summary
Central Admixture Pharmacy Services Inc. is recalling morphine in 0.9% sodium chloride (125 mg/25 mL, 5 mg/mL strength) supplied in 30 mL syringes. The recall affects 723 syringes distributed nationwide in the United States.
The recall was initiated because the manufacturer lacks validation data for sanitization cycles used in the manufacturing process. This means there is no documented assurance that the sterilization procedures are effective, creating a potential risk that the product may not be sterile.
Affected lots are: 17-271060 (expires 7/24/2023), 17-271252 (expires 7/26/2023), 17-271571 (expires 8/1/2023), 17-272471 (expires 8/16/2023), and 17-272785 (expires 8/22/2023). Patients and healthcare providers in possession of this product should stop use immediately and consult their healthcare provider if it has already been administered.
Healthcare facilities should identify and quarantine affected units. For more information, contact Central Admixture Pharmacy Services Inc. at 7935 Dunbrook Road, Suite C, San Diego, CA 92126.
The recalled product
- Product
- morphine in 0.9% sodium chloride, 125 mg/25 mL, (5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2041-2
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable Pharmaceutical
- Affected units
- 723
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot: 17-271060
- Exp. 7/24/2023
- 17-271252
- Exp. 7/26/2023
- 17-271571
- Exp. 8/1/2023
- 17-272471
- Exp. 8/16/2023
- 17-272785
- Exp. 8/22/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services Inc
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility assurance
See all →- HighArrowhead DE LLC Recalls Arrow-LOK Implants Due to Sterility Assurance Concerns
FDA (Devices) · 2026-08-26
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15
- SevereChloraPrep One-Step Applicators Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2026-07-08
- SevereArrow drainage and thoracentesis kits contain recalled supplier drugs
FDA (Devices) · 2026-06-24